仙乐健康(300791)：个护减值、激励落地 递表港交所焕新起航

Core Viewpoint - The company has issued a profit forecast for 2025, expecting a significant decline in net profit and has announced various strategic initiatives including stock incentive plans and a move to list on the Hong Kong Stock Exchange [1][4]. Group 1: 2025 Profit Forecast - The company anticipates a net profit attributable to shareholders for 2025 to be between 101 million to 151 million yuan, representing a year-on-year decline of 53% to 69% [1] - The non-recurring net profit is expected to be between 58 million to 86 million yuan, reflecting a decrease of 74% to 82% year-on-year [1] - For Q4 2025, the company projects a net loss attributable to shareholders between 109 million to 159 million yuan, with a non-recurring net loss between 158 million to 187 million yuan [1] Group 2: Asset Impairment and Business Strategy - The company has recognized impairment losses of 195 million yuan for BFPC and 57 million yuan for Hubei Yibenhui, totaling 252 million yuan [1] - The impairment of BFPC's assets is expected to optimize the company's business structure in the U.S. and improve profitability upon successful divestment [2] - The projected loss for the BF subsidiary in the first three quarters of 2025 is estimated at 130 million yuan, with potential for significant profit improvement post-divestment [2] Group 3: Stock Incentive and Employee Ownership Plans - The company has proposed a stock incentive plan for 2026, aiming to grant 2.2025 million shares, which is about 0.72% of the total share capital [3] - The performance targets for the stock incentive plan include revenue of no less than 5.09012 billion yuan in 2026, with expected growth rates of 5.7% and 8.3% for 2027 and 2028 respectively [3] - An employee stock ownership plan has also been announced, with a total fundraising target of no more than 32.0575 million yuan, involving up to 12 employees [3] Group 4: Listing on Hong Kong Stock Exchange - The company has officially submitted its prospectus to the Hong Kong Stock Exchange, aiming to leverage international capital market advantages [4] - Revenue from various regions for Q1-Q3 2025 shows that domestic and overseas markets contribute significantly, with over 60% of revenue coming from international operations [4] - The move to list in Hong Kong is expected to accelerate the company's global expansion and enhance its growth potential [4] Group 5: Adjusted Profit Forecast - Due to the impairment and other short-term challenges, the company has adjusted its profit forecasts for 2025-2027, now expecting net profits of 120 million, 390 million, and 480 million yuan respectively [4] - The year-on-year changes in profit forecasts are -63.3%, +222.1%, and +25.4% for the respective years [4] - The current stock price corresponds to a price-to-earnings ratio of 61, 19, and 15 times for 2025, 2026, and 2027 [4]